CBAY - Cymabay Therapeutics Inc Stock Price, Fair Value and News

$32.48

Market Closed

CBAY Stock Valuation Analysis

Valuation

Max Portfolio %

CBAY Price Action

CBAY RSI Chart

CBAY Stock Valuation Analysis

Valuation

Max Portfolio %

CBAY Valuation

CBAY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CBAY Fundamentals

CBAY Revenue

CBAY Earnings

CBAY Profitability

CBAY Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	31.1M
2022	0	0	0	0
2021	0	0	0	0
2017	5.4M	7.7M	4.8M	10.0M
2012	12.1M	9.1M	6.1M	3.0M
2011	0	0	0	15.1M
2010	0	0	0	800.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CEO	Mr. Sujal A. Shah
WEBSITE	cymabay.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	60